eCOA’s time has come. The market is currently estimated to be worth $2.3 billion, with projections showing it reaching nearly $5 billion by 2030. Despite this, paper still plays a prominent role for some clinical trials today.  

At first glance, paper may seem simple and familiar, even economical. However, in today’s regulatory and operational environment, paper COAs are not a risk averse choice when held to the standards of what sponsors, CROs, and regulators are looking for trial data to prove.  

‍

Patient adherence is a must for any clinical trial to be considered successful.  When patients consistently and accurately complete their electronic clinical outcome assessment (eCOAs) the quality and reliability of the data significantly improve, leading to more robust trial outcomes. 

However, maintaining high patient adherence can be challenging, particularly in long-term studies or complex assessments. This blog post explores effective strategies to optimize patient adherence in eCOA clinical trials, focusing on patient-centric design, clear communication, and strategic technology implementation.

‍